Dr. Nick Clemons is a Group Leader in the Oncogenic Signalling & Growth Control Program at the Peter MacCallum Cancer Centre in Melbourne, Australia. He was awarded his PhD for his research on the modulation of apoptotic pathways by cellular chaperones from the University of Melbourne in 2004 (based at Peter MacCallum Cancer Centre). This was followed by a Medical Research Council post-doctoral fellowship studying esophageal carcinogenesis with Prof. Rebecca Fitzgerald at the MRC Cancer Unit, Cambridge, UK, where he was also a Junior Research Fellow at Wolfson College, University of Cambridge. In 2008, Dr Clemons returned to the Peter MacCallum Cancer Centre to continue his research. In collaboration with Prof. Wayne Phillips he has built a vibrant research program on oesophageal cancer that spans basic biology and translational research areas. His work has focussed on the development of in vivo models to study the different stages of disease development and has led to the identification of Hedgehog signaling as an important driver of Barrett’s metaplasia. More recently he has developed patient derived xenograft models to evaluate novel therapies including the mutant p53 reactivator APR-246. This work has led to a phase II clinical trial of APR-246 in chemoresistant esophageal cancer, which will begin in late 2016.
2016 Victorian Cancer Agency (VCA) Fellowship
2016 NIDDK and NCI Travel Award
2015 Cancer Therapeutics CRC Travel Award
2010 VCA Early Career Grant
2004-2007 MRC UK Career Development Fellowship